Search

05/10/2021 Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease
Gaig, C, Compta, Y, Heidbreder, A, Marti, MJ, Titulaer, MJ, Crijnen, Y, Hogl, B, Lewerenz, J, Erro, ME, Garcia-Monco, JC, Nigro, P, Tambasco, N, Patalong-Ogiewa, M, Erdler, M, Macher, S, Berger-Sieczkowski, E, Hoftberger, R, Geis, C, Hutterer, M, Milan-Tomas, A, Martin-Bastida, A, Manzanares, LL, Quintas, S, Hoglinger, GU, Mohn, N, Schoberl, F, Thaler, FS, Asioli, GM, Provini, F, Plazzi, G, Berganzo, K, Blaabjerg, M, Bruggemann, N, Farias, T, Ng, CF, Giordana, C, Herrero-San Martin, A, Huebra, L, Kotschet, K, Liendl, H, Montojo, T, Morata, C, Perez, JP, Puertas, I, Seifert-Held, T, Seitz, C, Simabukuro, MM, Tellez, N, Villacieros-Alvarez, J, Willekens, B, Sabater, L, Iranzo, A, Cano, JS, Dalmau, J, Graus, F. Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease. NEUROLOGY. 2021; 97(14)DOI:10.1212/WNL.0000000000012639. PMID:34380749. IF:12.258(Q1/1D).
01/10/2021 A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data
Pagano, G, Boess, FG, Taylor, KI, Ricci, B, Mollenhauer, B, Poewe, W, Boulay, A, Anzures-Cabrera, J, Vogt, A, Marchesi, M, Post, A, Nikolcheva, T, Kinney, GG, Zago, WM, Ness, DK, Svoboda, H, Britschgi, M, Ostrowitzki, S, Simuni, T, Marek, K, Koller, M, Sevigny, J, Doody, R, Fontoura, P, Umbricht, D, Bonni, A, PASADENA Investigators, Bejr-Kasem, H, Bojarsky J.K., Prasinezumab Study Grp. A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data. Frontiers in Neurology. 2021; 12DOI:10.3389/fneur.2021.705407. PMID:34659081. IF:4.086(Q2/5D).
01/09/2021 Gray Matter Vulnerabilities Predict Longitudinal Development of Apathy in Huntington's Disease
De Paepe, AE, Ara, A, Garcia-Gorro, C, Martinez-Horta, S, Perez-Perez, J, Kulisevsky, J, Rodriguez-Dechicha, N, Vaquer, I, Subira, S, Calopa, M, Munoz, E, Santacruz, P, Ruiz-Idiago, J, Mareca, C, de Diego-Balaguer, R, Camara, E. Gray Matter Vulnerabilities Predict Longitudinal Development of Apathy in Huntington's Disease. MOVEMENT DISORDERS. 2021; 36(9)DOI:10.1002/mds.28638. PMID:33998063. IF:9.698(Q1/1D).
01/08/2021 The role of glutamatergic neurotransmission in the motor and non-motor symptoms in Parkinson's disease: Clinical cases and a review of the literature
Pagonabarraga, J, Tinazzi, M, Caccia, C, Jost, WH. The role of glutamatergic neurotransmission in the motor and non-motor symptoms in Parkinson's disease: Clinical cases and a review of the literature. JOURNAL OF CLINICAL NEUROSCIENCE. 2021; 90DOI:10.1016/j.jocn.2021.05.056. PMID:34275546. IF:2.116(Q4/9D).